Association of creatine kinase elevation with clinical outcomes in chronic myeloid leukemia: a retrospective cohort study

References

• Caldemeyer L, Dugan M, Edwards J, et al. Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia. Curr Hematol Malig Rep. 2016;11(2):71–79.
   PubMed Web of Science ®Google Scholar
• Kekäle M, Peltoniemi M, Airaksinen M. Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment. Patient Prefer Adherence. 2015;9:1733–1740.
   PubMed Web of Science ®Google Scholar
• Marin D, Bazeos A, Mahon F-X, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381–2388.
   PubMed Web of Science ®Google Scholar
• Uz B, Dolasik I. An unexpected and devastating adverse event of dasatinib: rhabdomyolysis. Leuk Res Rep. 2016;5:1–2.
   PubMedGoogle Scholar
• Gordon JK, Magid SK, Maki RG, et al. Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec). Leuk Res. 2010;34(6):827–829.
   PubMed Web of Science ®Google Scholar
• Hewitt JD, Rusnak DA, Cox-Kennett N, et al. HyperCKemia in CML patients on imatinib mesylate. Blood. 2007;110(11):2965–2965.
   PubMedGoogle Scholar
• O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994–1004.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–2340.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Saglio G, Hughes T, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044–1054.
   PubMed Web of Science ®Google Scholar
• Malkan UY, Gunes G, Etgul S, et al. Management of de novo CML and imatinib-induced acute rhabdomyolysis with the second-generation TKI, dasatinib. Ann Pharmacother. 2015;49(6):740–742.
   PubMed Web of Science ®Google Scholar
• Penel N, Blay J-Y, Adenis A. Imatinib as a possible cause of severe rhabdomyolysis. N Engl J Med. 2008;358(25):2746–2747.
   PubMed Web of Science ®Google Scholar
• Moscetti L, Nelli F, Ruggeri EM. Rhabdomyolysis from erlotinib: a case report. Tumori. 2011;97(3):415–416.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Cortes JE, Lipton JH, et al. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol. 2014;89(10):947–953.
   PubMed Web of Science ®Google Scholar
• Tokuhira M, Kimura Y, Sugimoto K, et al. Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase. Med Oncol. 2018;35(3):38.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260–2270.
   PubMed Web of Science ®Google Scholar
• Al-Ali HK, Krahl R, Orth M, et al. Persistently increased creatine kinase levels in patients with chronic myeloid leukemia treated with imatinib correlate with major cytogenetic remission. Blood. 2004;104(11):2933–2933.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. 2021; [cited 2019 Jul 8]. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf
   Google Scholar
• Mantel N, Byar D. Evaluation of response-time data involving transient states: an illustration using heart-transplant data. J Am Stat Assoc. 1974;69(345):81–86.
   Web of Science ®Google Scholar
• Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias . Stat Med. 1984;3(1):35–44.
   PubMed Web of Science ®Google Scholar
• Bower H, Björkholm M, Dickman PW, et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851–2857.
   PubMed Web of Science ®Google Scholar
• Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30(8):1648–1671.
   PubMed Web of Science ®Google Scholar
• Cervellin G, Comelli I, Benatti M, et al. Non-traumatic rhabdomyolysis: background, laboratory features, and acute clinical management. Clin Biochem. 2017;50(12):656–662.
   PubMed Web of Science ®Google Scholar
• Tapson VF. Imatinib as a possible cause of severe rhabdomyolysis. Arch Intern Med. 2000;160:3415–3420.
   PubMedGoogle Scholar
• Hohenegger M. Drug induced rhabdomyolysis. Curr Opin Pharmacol. 2012;12(3):335–339.
   PubMed Web of Science ®Google Scholar
• Franceschino A, Tornaghi L, Benemacher V, et al. Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib. Haematologica. 2008;93(2):317–318.
   PubMed Web of Science ®Google Scholar
• Dean AR, Kantarjian HM, O'Brien S, et al. Causes of death for patients with chronic myeloid leukemia (CML) in chronic phase (CP) treated with imatinib. Blood. 2009;114(22):4279–4279.
   PubMedGoogle Scholar
• Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30(1):48–56.
   PubMed Web of Science ®Google Scholar
• Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984;63(4):789–799.
   PubMed Web of Science ®Google Scholar
• Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa writing committee for the collaborative CML prognostic factors project group. J Natl Cancer Inst. 1998;90(11):850–859.
   PubMedGoogle Scholar
• Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36(3):231–237.
   PubMed Web of Science ®Google Scholar
• Maiti A, Cortes JE, Patel KP, et al. Long-term results of frontline dasatinib in chronic myeloid leukemia. Cancer. 2020;126(7):1502–1511.
   PubMed Web of Science ®Google Scholar
• Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12(8):908–916.
   PubMed Web of Science ®Google Scholar
• Will Y, Dykens JA, Nadanaciva S, et al. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol Sci. 2008;106(1):153–161.
   PubMed Web of Science ®Google Scholar
• Caocci G, Maioli MA, Atzeni S, et al. Absence of histological myopathy in chronic myeloid leukemia patients complaining of muscle spasms and myalgia during treatment with nilotinib. Leuk Res. 2012;36(9):e206–e208.
   PubMed Web of Science ®Google Scholar
• Janssen L, Frambach SJCM, Allard NAE, et al. Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Leukemia. 2019;33(8):2116–2120.
   PubMed Web of Science ®Google Scholar